home / stock / snse / snse news

SNSE News and Press, Sensei Biotherapeutics Inc. From 06/13/23

Stock Information
Company Name: Sensei Biotherapeutics Inc.
Stock Symbol: SNSE
Market: NASDAQ
Website: senseibio.com
Menu
SNSE SNSE Quote SNSE Short SNSE News SNSE Articles SNSE Message Board
Get SNSE Alerts

News, Short Squeeze, Breakout and More Instantly...
SNSE - Sensei Biotherapeutics to Host Virtual Key Opinion Leader Event, "A New Vista for Cancer Care: Exploring SNS-101's Potential as a Transformative Treatment Option for Patients with Solid Tumors"

- Featuring Dr. James Gulley, Co-Director of the Center for Immuno-Oncology at the National Cancer Institute (NCI) and internationally recognized expert on cancer immunotherapy - - Pre-registration available for live event, to be held Tuesday, June 27, 2023 at 2:00 p.m. ET - BOSTO...
SNSE - Sensei Biotherapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of SNS-101, a Conditionally Active VISTA-blocking Antibody, for the Treatment of Advanced Solid Tumors

- Topline Phase 1 monotherapy and initial combination data expected in 2024 - BOSTON, June 01, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical-stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer...

SNSE - Sensei Biotherapeutics to Participate in Jefferies Global Healthcare Conference

BOSTON, May 31, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer patients, today announced that John Celebi, President and Chief Executive Officer, wil...

SNSE - Sensei Biotherapeutics GAAP EPS of -$0.33 beats by $0.02

2023-05-09 08:52:05 ET Sensei Biotherapeutics press release ( NASDAQ: SNSE ): Q1 GAAP EPS of -$0.33 beats by $0.02 . Cash, cash equivalents and marketable securities were $95.5 million as of March 31, 2023, as compared to $107.1 million as of December 31, 2022. Sensei ...
SNSE - Sensei Biotherapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights

- Investigational New Drug (IND) application for SNS-101 cleared by U.S. Food and Drug Administration (FDA) with first patient dose in Phase 1/2 trial expected in mid-2023 - - Signing of key collaborations underscore potential of conditional activation and VISTA mechanism - - AA...

SNSE - FENG, ALXO and GFAI among mid-day gainers

2023-04-21 13:53:45 ET Gainers: Presto Automation ( PRST ) +49% . CBL International Limited ( BANL ) +34% . EyePoint Pharmaceuticals EYPT +31% . Asset Entities ( ASST ) +25% . ContextLogic ( WISH ) +24% . Mullen Automotive ( MU...

SNSE - EVBG and SATX among pre-market losers

2023-04-21 09:15:38 ET Satixfy Communications ( SATX ) -17% . Aditxt ( ADTX ) -11% . Everbridge ( EVBG ) -10% . Augmedix ( AUGX ) -7% . Sensei Biotherapeutics ( SNSE ) -7% . Blackboxstocks ( BLBX ) -6% . Big Lots ( ...
SNSE - Sensei gains FDA IND clearance for solid tumors candidate

2023-04-20 08:18:28 ET Sensei Biotherapeutics ( NASDAQ: SNSE ) received US FDA approval for its Investigational New Drug ( IND ) application for SNS-101, an antibody for solid tumors. The company will now proceed with a phase 1 trial of SNS-101 as both monotherapy and ...

SNSE - Sensei Biotherapeutics Announces IND Clearance by U.S. FDA Enabling Phase 1 Initiation for SNS-101, a Conditionally Active VISTA-Blocking Antibody

BOSTON, April 20, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investi...

SNSE - Sensei Biotherapeutics Presents New Preclinical Data on SNS-103 Targeting ENTPDase1 (CD39) at the American Association for Cancer Research (AACR) Annual Meeting 2023

BOSTON, April 18, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today presented new preclinical data on its SNS-103 program aimed at developing a condit...
Previous 10 Next 10